Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatology international Huang, C. F., Iio, E. n., Jun, D. W., Ogawa, E. n., Toyoda, H. n., Hsu, Y. C., Haga, H. n., Iwane, S. n., Enomoto, M. n., Lee, D. H., Wong, G. n., Liu, C. H., Tada, T. n., Chuang, W. L., Cheung, R. n., Hayashi, J. n., Tseng, C. H., Yasuda, S. n., Tran, S. n., Kam, L. n., Henry, L. n., Jeong, J. Y., Nomura, H. n., Park, S. H., Nakamuta, M. n., Huang, J. F., Tai, C. M., Lo, G. H., Lee, M. H., Yang, H. I., Kao, J. H., Tamori, A. n., Eguchi, Y. n., Ueno, Y. n., Furusyo, N. n., Tanaka, Y. n., Yu, M. L., Nguyen, M. H. 2019


One-third of the global hepatitis C virus (HCV) burden is found in Asia. Real-world data from diverse East Asian cohorts remain limited. This study addressed the real-world status of direct-acting antiviral (DAA) therapy among patients from East Asia.Chronic hepatitis C (CHC) patients from clinical sites in Japan, Taiwan, South Korea, and Hong Kong were recruited in the REAL-C registry, an observational chart review registry. The primary outcome was sustained virologic response (SVR12, HCV RNA PCR?

View details for DOI 10.1007/s12072-019-09974-z

View details for PubMedID 31463665